相关实验视频
Updated: May 4, 2026
07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
23.1K
长期使用lokivetmab (Cytopoint®) 治疗无形性狗
Margaret Gober1, Deb Amodie2, Marnie Mellencamp2
1Zoetis LLC, 10 Sylvan Way, NJ, Parsippany, 07054, USA. Margaret.Gober@zoetis.com.
BMC veterinary research
|March 26, 2025
概括
洛基维特马布有效地长期管理犬类无性皮炎 (CAD),大多数狗显示持续减少和主人满意度. 这种治疗简化了护理,减少了对其他药物的需求.
科学领域:
- 兽医皮肤病学 兽医皮肤病学
- 免疫治疗犬类无氧皮肤炎 (CAD) 的免疫疗法
背景情况:
- 洛基维特马布在短期CAD治疗中是有效的.
- 美国标签剂量的长期疗效和安全性仍未得到充分研究.
研究的目的:
- 为了评估lokivetmab的长期 (12个月) 疗效和主人的满意度,用于在美国标签剂量下治疗犬皮炎 (CAD).
- 评估lokivetmab在长时间内对和皮肤病变的影响.
主要方法:
- 一项干预性队列研究跟踪了患有CAD的狗,每4-8周接受一次lokivetmab注射.
- 业主完成了每两周一次的评估 (PVAS);调查人员在基线和随访时记录了皮肤损伤得分 (CADESI-4,VetVAS).
- 纳入标准要求狗在初始阶段在PVAS上达到<36毫米.
主要成果:
- 在整个12个月的研究中,88%的狗保持了平均的得分低于36毫米.
- 31%的狗每两周都有不超过36毫米的,11%的狗保持不超过20毫米的.
- 据报道,业主满意度很高 (93%),88%的人打算继续治疗,80%的人减少其他药物.
结论:
- 洛基维特马布在12个月的时间内在美国标签剂量下,在治疗犬类亚托皮炎 (CAD) 中表现出持续的疗效.
- 治疗显著减少了和改善了业主报告的生活质量.
- 洛基维特马布 (Lokivetmab) 提供了一种方便和有效的长期治疗选择,用于治疗犬类亚托皮炎.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
01:01Hypersensitivity Reactions: Cytolytic Reactions
208
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
208